Takeda Pharmaceuticals America, Inc.
NDC labeler codes: 47783, 54092, 59417, 63020, 64764, 68875
What is a labeler?
The company whose name is on the package and in the FDA’s National Drug Code (NDC) Directory. It may make the medicine itself or sell medicine made by another company. The first part of every NDC code identifies the labeler.
Official FDA data only
Products, approvals and recalls come from the FDA (NDC Directory, Drugs@FDA, enforcement reports). Recalls are linked to this company by the NDC labeler code on the recalled product.
Questions about your medicine: ask your doctor or pharmacist. In an emergency, call 911.
Prescription medicines
- Lisdexamfetamine dimesylateVyvanse, Arynta · 13 products
- Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfateAdderall, Adderall XR, Mixed Salts of a Single Entity Amphetamine Product XR · 10 products
- Lanthanum carbonateFosrenol · 5 products
- Ponatinib hydrochlorideIclusig · 4 products
- Alogliptin benzoate and pioglitazone hydrochlorideOseni · 4 products
- GuanfacineIntuniv · 4 products
- MesalaminePentasa, Rowasa, Lialda · 4 products
- CarbamazepineTegretol XR, Carbatrol, Equetro · 3 products
- PioglitazoneActos · 3 products
- VedolizumabEntyvio, Entyvio Pen · 3 products
- BrigatinibAlunbrig · 3 products
- LansoprazolePrevacid Solutab, Prevacid · 3 products
- VortioxetineTrintellix · 3 products
- IxazomibNinlaro · 3 products
- AlogliptinNesina · 3 products
- LubiprostoneAmitiza, Amitza · 2 products
- Pioglitazone and glimepirideDuetact · 2 products
- FebuxostatUloric · 2 products
- Lanadelumab-flyoTakhzyro · 2 products
- FruquintinibFruzaqla · 2 products
- Alogliptin and metformin hydrochlorideKazano · 2 products
- PrucaloprideMotegrity · 2 products
- DexlansoprazoleDexilant · 2 products
- TeduglutideGattex · 1 product
- AnagrelideAgrylin · 1 product
- BortezomibBoruzu, Velcade · 1 product
- BudesonidePulmicort Flexhaler, Pulmicort Respules, Uceris · 1 product
- Velaglucerase alfaVpriv · 1 product
- IcatibantSajazir, Firazyr · 1 product
- EcallantideKalbitor · 1 product
- Pioglitazone and metformin hydrochlorideActoplus Met · 1 product
- IdursulfaseElaprase · 1 product
- MaribavirLivtencity · 1 product
- RamelteonRozerem · 1 product
FDA applications for these products
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| February 9, 2024 | NDA213976 | Budesonide EOHILIA | Takeda Pharms USA |
| November 8, 2023 | NDA217564 | Fruquintinib FRUZAQLA | Takeda Pharms USA |
| September 27, 2023 | BLA761133 | Vedolizumab ENTYVIO | Takeda Pharms USA |
| November 23, 2021 | NDA215596 | Maribavir LIVTENCITY | Takeda Pharms USA |
| December 14, 2018 | NDA210166 | Prucalopride MOTEGRITY | Takeda Pharms USA |
| August 23, 2018 | BLA761090 | Lanadelumab-flyo TAKHZYRO | Dyax Corp. |
| June 20, 2017 | NDA022063 | Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate MYDAYIS | Takeda Pharms USA |
| April 28, 2017 | NDA208772 | Brigatinib ALUNBRIG | Takeda Pharms USA |
| January 28, 2017 | NDA208510 | Lisdexamfetamine dimesylate VYVANSE | Takeda Pharms USA |
| November 20, 2015 | NDA208462 | Ixazomib NINLARO | Takeda Pharms USA |
| September 24, 2014 | NDA204734 | Lanthanum carbonate FOSRENOL | Takeda Pharms USA |
| May 20, 2014 | BLA125476 | Vedolizumab ENTYVIO | Takeda Pharms USA |
| September 30, 2013 | NDA204447 | Vortioxetine TRINTELLIX | Takeda Pharms USA |
| January 25, 2013 | NDA022271 | Alogliptin NESINA | Takeda Pharms USA |
| January 25, 2013 | NDA022426 | Alogliptin benzoate and pioglitazone hydrochloride OSENI | Takeda Pharms USA |
| January 25, 2013 | NDA203414 | Alogliptin and metformin hydrochloride KAZANO | Takeda Pharms USA |
| December 21, 2012 | NDA203441 | Teduglutide GATTEX KIT | Takeda Pharms USA |
| December 14, 2012 | NDA203469 | Ponatinib hydrochloride ICLUSIG | Takeda Pharms USA |
| August 25, 2011 | NDA022150 | Icatibant FIRAZYR | Takeda Pharms USA |
| February 26, 2010 | BLA022575 | Velaglucerase alfa VPRIV | Shire Human Genetic |
| December 1, 2009 | BLA125277 | Ecallantide KALBITOR | Dyax Corp. |
| September 2, 2009 | NDA022037 | Guanfacine INTUNIV | Takeda Pharms USA |
| February 13, 2009 | NDA021856 | Febuxostat ULORIC | Takeda Pharms USA |
| January 30, 2009 | NDA022287 | Dexlansoprazole DEXILANT | Takeda Pharms USA |
| February 23, 2007 | NDA021977 | Lisdexamfetamine dimesylate VYVANSE | Takeda Pharms USA |
Show the other 15 applications
| Approved | Application | Medicine | Sponsor |
|---|---|---|---|
| January 16, 2007 | NDA022000 | Mesalamine LIALDA | Takeda Pharms USA |
| July 28, 2006 | NDA021925 | Pioglitazone and glimepiride DUETACT | Takeda Pharms USA |
| July 24, 2006 | BLA125151 | Idursulfase ELAPRASE | Shire |
| January 31, 2006 | NDA021908 | Lubiprostone AMITIZA | Sucampo Pharma LLC |
| August 29, 2005 | NDA021842 | Pioglitazone and metformin hydrochloride ACTOPLUS MET | Takeda Pharms USA |
| July 22, 2005 | NDA021782 | Ramelteon ROZEREM | Takeda Pharms USA |
| October 26, 2004 | NDA021468 | Lanthanum carbonate FOSRENOL | Takeda Pharms USA |
| May 13, 2003 | NDA021602 | Bortezomib VELCADE | Takeda Pharms USA |
| August 30, 2002 | NDA021428 | Lansoprazole PREVACID | Takeda Pharms USA |
| October 11, 2001 | NDA021303 | Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate ADDERALL XR 10, ADDERALL XR 15, ADDERALL XR 20 | Takeda Pharms USA |
| July 15, 1999 | NDA021073 | Pioglitazone ACTOS | Takeda Pharms USA |
| September 30, 1997 | NDA020712 | Carbamazepine CARBATROL | Takeda Pharms USA |
| March 14, 1997 | NDA020333 | Anagrelide AGRYLIN | Takeda Pharms USA |
| May 10, 1995 | NDA020406 | Lansoprazole PREVACID | Takeda Pharms USA |
| May 10, 1993 | NDA020049 | Mesalamine PENTASA | Takeda Pharms USA |
The sponsor is the company that holds the FDA application; it can differ from the labeler.
Recall timeline
2019
-
May 13, 2019 · Class II · Terminated · D-1295-2019 · Lubiprostone
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.
Amitiza (lubiprostone) capsules, 24 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-240-60
-
May 13, 2019 · Class II · Terminated · D-1294-2019 · Lubiprostone
Labeling: Label mix-up. Amitiza 8 mcg capsules are being recalled because 24 mcg capsules were found in a 8 mcg trade 60 ct. bottle. Amitiza 24 mcg capsules are being recalled because a sealed 60 ct. bottle contained only 8 mcg capsules, this incident is being considered as a labeling mix-up issue.
Amitiza (lubiprostone) capsules, 8 mcg, 60-count bottle, Rx only, Manufactured by: Sucampo Pharma Americas, LLC, NDC 64764-080-60
2018
-
November 6, 2018 · Class III · Terminated · D-0286-2019 · Lubiprostone
Failed Impurities/Degradation Specifications:Elevated levels of a known impurity in the 20-month stability sample testing.
AMITIZA (lubiprostone) capsules 8 mcg. 60-count bottle, Rx Only. Marketed by: Sucampo Pharma Americas, LLC, Rockville MD 20850 and Takeda Pharmaceuticals America, Inc. Deerfield, IL 60015. Active Ingredient made in Japan
2017
-
March 17, 2017 · Class II · Terminated · D-0625-2017 · Ecallantide
Presence of Particulate Matter: Glass
Kalbitor (ecallantide), 10mg/mL, packaged in 3 vials per Carton, Rx Only, Dynax Corp., Burlington, MA. NDC47783-101-01
2016
-
December 2, 2016 · Class III · Terminated · D-0432-2017 · Mesalamine
Presence of Foreign Tablets/Capsules; 500 mg capsules were found in bottles labeled to contain 250 mg capsules
Pentasa (mesalamine) Controlled-Release Capsules, 250 mg, 240 count bottle, Rx only, Manufactured for Shire US Inc., Lexington, MA --- NDC 54092-189-81
-
September 2, 2016 · Class III · Terminated · D-0006-2017 · Lisdexamfetamine dimesylate
Presence of Foreign Tablets/Capsules
Vyvanse (lisdexamfetamine dimesylate) Capsules 30 mg, 100 count bottle, Rx Only, Manufactured for: Shire US, Inc., Lexington, MA 02421, NDC 59417-103-10
2014
-
March 14, 2014 · Class I · Terminated · D-1251-2014 · Velaglucerase alfa
Presence of Particulate Matter; Particulates identified as stainless steel and barium sulfate.
VPRIV¿ (velaglucerase alfa for injection) , Lyophilized Powder, 400 Units/vial, Rx Only. Shire Human Genetic Therapies, Inc. 300 Shire Way, Lexington, MA 02421. NDC: 54092-701-04.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Next steps
- Find a pharmacy near youAsk which company made your medicine and whether it is recalled
- Latest FDA drug recallsAll companies, newest first
- All drug companiesA to Z
- All prescription drugs A to ZSearch by generic, brand or Spanish name
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026